Ankyra in the News
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Press Releases
Ankyra Therapeutics Presents Preliminary Canine Clinical Data with cANK-101 Supporting Therapeutic Potential of Anchored Immunotherapy
Preliminary data of anchored canine IL-12 (cANK-101) in dogs with malignant melanoma demonstrates tolerable safety and early signs of biologic activity. Human ANK-101 is an IL-12- based anchored immunotherapy with IND submission planned for late 2023 BOSTON, MA, April...
Ankyra Therapeutics Appoints Experienced Financial Executive Stephen Gorgol as Chief Financial Officer
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced the appointment of Stephen Gorgol as chief financial officer. Mr. Gorgol, a proven financial leader within the biotech industry, joins...
Ankyra Therapeutics Announces Collaboration to Evaluate ANK-101 in Early Clinical Trials Focused on Lung Cancer
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that is has entered into a strategic collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson*. The collaboration will...
Ankyra Therapeutics Appoints Leisha A. Emens, M.D., Ph.D., as Senior Vice President, Translational Research
Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that Leisha A. Emens, M.D., Ph.D., has been appointed as senior vice president, translational research. Dr. Emens is an experienced...
Ankyra Therapeutics Presents Positive Preclinical Data Supporting Advancement of ANK-101 into Clinical Studies for Treatment of Solid Tumors
Data to be presented during Society for Immunotherapy of Cancer 37th Annual Meeting BOSTON — Ankyra Therapeutics, a biotech company developing targeted immune activating agents for the treatment of cancer, today announced that new, preclinical data highlighting the...
Ankyra Therapeutics Appoints Joseph J. Elassal, M.D., MBA, a Veteran Immuno-oncology Expert, as Chief Medical Officer
BOSTON, Mass.--(BUSINESS WIRE)— Ankyra Therapeutics, a company developing targeted immune potentiating agents for the treatment of cancer, today announced the appointment of Joseph J. Elassal, M.D., as chief medical officer. Dr. Elassal will fill the role formerly...
